Literature DB >> 23074428

Epilepsy care in ontario: an economic analysis of increasing access to epilepsy surgery.

James M Bowen1, O Carter Snead, Kiran Chandra, Gord Blackhouse, Ron Goeree.   

Abstract

BACKGROUND: In August 2011 a proposed epilepsy care model was presented to the Ontario Health Technology Advisory Committee (OHTAC) by an Expert Panel on a Provincial Strategy for Epilepsy Care in Ontario. The Expert Panel recommended leveraging existing infrastructure in the province to provide enhanced capacity for epilepsy care. The point of entry for epilepsy care and the diagnostic evaluation for surgery candidacy and the epilepsy surgery would occur at regional and district epilepsy centres in London, Hamilton, Toronto, and Ottawa and at new centres recommended for northern and eastern Ontario. This economic analysis report was requested by OHTAC to provide information about the estimated budgetary impact on the Ontario health care system of increasing access to epilepsy surgery and to examine the cost-effectiveness of epilepsy surgery in both children and adults.
METHODS: A prevalence-based "top-down" health care system budgetary impact model from the perspective of the Ministry of Health and Long-Term Care was developed to estimate the potential costs associated with expanding health care services to increase access to epilepsy care in general and epilepsy surgery in particular. A 5-year period (i.e., 2012-2016) was used to project annual costs associated with incremental epilepsy care services. Ontario Health Survey estimates of epilepsy prevalence, published epilepsy incidence data, and Canadian Census results for Ontario were used to approximate the number of individuals with epilepsy in the province. Applying these population estimates to data obtained from a recent field evaluation study that examined patterns of care and costs associated with epilepsy surgery in children, a health care system budget impact was calculated and the total costs and incremental costs associated with increasing access to surgery was estimated. In order to examine the cost-effectiveness of epilepsy surgery in children, a decision analysis compared epilepsy surgery to continued medical management in children with medically intractable epilepsy. Data from the field evaluation were combined with various published data to estimate the costs and outcomes for children with drug-refractory epilepsy over a 20-year period. Outcomes were defined as the number of quality-adjusted life years (QALYs) accumulated over 20 years following epilepsy surgery.
RESULTS: There are about 20,981 individuals with medically intractable epilepsy in Ontario. Of these, 9,619 (1,441 children and 8,178 adults) could potentially be further assessed at regional epilepsy centres for suitability for epilepsy surgery, following initial evaluation at a district epilepsy care centre. The health care system impact analysis related to increasing access to epilepsy surgery in the Ontario through the addition of epilepsy monitoring unit (EMU) beds with video electroencephalography (vEEG) monitoring (total capacity of 15 pediatric EMU beds and 35 adult EMU beds distributed across the province) and the associated clinical resources is estimated to require an incremental $18.1 million (Cdn) annually over the next 5 years from 2012 to 2016. This would allow for about 675 children and 1050 adults to be evaluated each year for suitability for epilepsy surgery representing a 150% increase in pediatric epilepsy surgery evaluation and a 170% increase in adult epilepsy surgery evaluation. Epilepsy surgery was found to be cost-effective compared to continued medical management in children with drug-refractory epilepsy with the incremental cost-effectiveness ratio of $25,020 (Cdn) to $69,451 (Cdn) per QALY for 2 of the scenarios examined. In the case of choosing epilepsy surgery versus continued medical management in children known to be suitable for surgery, the epilepsy surgery was found to be less costly and provided greater clinical benefit, that is, it was the dominant strategy.
CONCLUSION: Epilepsy surgery for medically intractable epilepsy in suitable candidates has consistently been found to provide favourable clinical outcomes and has been demonstrated to be cost-effective in both adult and child patient populations. The first step to increasing access to epilepsy surgery is to provide access to evidence-based care for all patients with epilepsy, both adults and children, through the provision of resources to expand EMU bed capacity and associated clinical personnel across the province of Ontario.

Entities:  

Mesh:

Year:  2012        PMID: 23074428      PMCID: PMC3428718     

Source DB:  PubMed          Journal:  Ont Health Technol Assess Ser        ISSN: 1915-7398


  17 in total

1.  Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.

Authors:  N B Fountain; P C Van Ness; R Swain-Eng; S Tonn; C T Bever
Journal:  Neurology       Date:  2011-01-04       Impact factor: 9.910

2.  Proposed criteria for referral and evaluation of children for epilepsy surgery: recommendations of the Subcommission for Pediatric Epilepsy Surgery.

Authors:  J Helen Cross; Prasanna Jayakar; Doug Nordli; Olivier Delalande; Michael Duchowny; Heinz G Wieser; Renzo Guerrini; Gary W Mathern
Journal:  Epilepsia       Date:  2006-06       Impact factor: 5.864

Review 3.  Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Authors:  J Wilby; A Kainth; N Hawkins; D Epstein; H McIntosh; C McDaid; A Mason; S Golder; S O'Meara; M Sculpher; M Drummond; C Forbes
Journal:  Health Technol Assess       Date:  2005-04       Impact factor: 4.014

4.  Essential services, personnel, and facilities in specialized epilepsy centers--revised 2010 guidelines.

Authors:  David M Labiner; Anto I Bagic; Susan T Herman; Nathan B Fountain; Thaddeus S Walczak; Robert J Gumnit
Journal:  Epilepsia       Date:  2010-11       Impact factor: 5.864

5.  Early identification of refractory epilepsy.

Authors:  P Kwan; M J Brodie
Journal:  N Engl J Med       Date:  2000-02-03       Impact factor: 91.245

6.  Burden of epilepsy: the Ontario Health Survey.

Authors:  S Wiebe; D R Bellhouse; C Fallahay; M Eliasziw
Journal:  Can J Neurol Sci       Date:  1999-11       Impact factor: 2.104

7.  Cost-effectiveness of pediatric epilepsy surgery compared to medical treatment in children with intractable epilepsy.

Authors:  Elysa Widjaja; Bing Li; Corrine Davies Schinkel; Lisa Puchalski Ritchie; James Weaver; O Carter Snead; James T Rutka; Peter C Coyte
Journal:  Epilepsy Res       Date:  2011-03       Impact factor: 3.045

8.  National and regional prevalence of self-reported epilepsy in Canada.

Authors:  José F Tellez-Zenteno; Margarita Pondal-Sordo; Suzan Matijevic; Samuel Wiebe
Journal:  Epilepsia       Date:  2004-12       Impact factor: 5.864

9.  Health resource use in epilepsy: Significant disparities by age, gender, and aboriginal status.

Authors:  Nathalie Jetté; Hude Quan; Peter Faris; Stafford Dean; Bing Li; Andrew Fong; Samuel Wiebe
Journal:  Epilepsia       Date:  2007-12-28       Impact factor: 5.864

10.  Life 12 years after temporal lobe epilepsy surgery: a long-term, prospective clinical study.

Authors:  Taner Tanriverdi; Nicole Poulin; Andre Olivier
Journal:  Seizure       Date:  2008-02-20       Impact factor: 3.184

View more
  9 in total

1.  Neurologists' knowledge of and attitudes toward epilepsy surgery: a national survey.

Authors:  Jodie I Roberts; Chantelle Hrazdil; Samuel Wiebe; Khara Sauro; Michelle Vautour; Natalie Wiebe; Nathalie Jetté
Journal:  Neurology       Date:  2014-12-10       Impact factor: 9.910

Review 2.  Surgical management of epilepsy.

Authors:  Nathalie Jette; Aylin Y Reid; Samuel Wiebe
Journal:  CMAJ       Date:  2014-06-09       Impact factor: 8.262

3.  Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations.

Authors:  Jesse Elliott; Sasha van Katwyk; Bláthnaid McCoy; Tammy Clifford; Beth K Potter; Becky Skidmore; George A Wells; Doug Coyle
Journal:  Pharmacoeconomics       Date:  2019-10       Impact factor: 4.981

Review 4.  Seizure outcomes in nonresective epilepsy surgery: an update.

Authors:  Dario J Englot; Harjus Birk; Edward F Chang
Journal:  Neurosurg Rev       Date:  2016-05-21       Impact factor: 3.042

Review 5.  Electrical stimulation for drug-resistant epilepsy: an evidence-based analysis.

Authors:  A Chambers; J M Bowen
Journal:  Ont Health Technol Assess Ser       Date:  2013-10-01

6.  Mitochondrial damage in hippocampal neurons of rats with epileptic protein expression of Fas and caspase-3.

Authors:  Junqiang Feng; Lifang Feng; Guiru Zhang
Journal:  Exp Ther Med       Date:  2018-07-13       Impact factor: 2.447

Review 7.  Bridging the Gap between Evidence and Practice for Adults with Medically Refractory Temporal Lobe Epilepsy: Is a Change in Funding Policy Needed to Stimulate a Shift in Practice?

Authors:  Alireza Mansouri; Abdulrahman Aldakkan; Magda J Kosicka; Jean-Eric Tarride; Taufik A Valiante
Journal:  Epilepsy Res Treat       Date:  2015-12-07

8.  Diagnostic value and prognostic evaluation of dynamic video-electroencephalogram monitoring in children with epilepsy.

Authors:  Xiaobo Wu; Ying Su; Wei Liu; Xiaoyu Jia; Yanling Zhang; Xinyang Zhang; Guilan Wang
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

9.  Early economic evaluation of MRI-guided laser interstitial thermal therapy (MRgLITT) and epilepsy surgery for mesial temporal lobe epilepsy.

Authors:  Elysa Widjaja; Tina Papastavros; Beate Sander; Carter Snead; Petros Pechlivanoglou
Journal:  PLoS One       Date:  2019-11-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.